Diabetic Retinopathy Market is expected to reach USD 13.04 billion by 2026| Bayer AG, Pfizer Inc., PAREXEL International Corp., Quark Pharmaceuticals Inc., Thrombogenic NV, etc.

Based on current analysis, the global diabetic retinopathy market was valued at USD 7.39 billion in 2018 and is expected to reach USD 13.04 billion by 2026, at a CAGR of 7.3%. Diabetic retinopathy is a diabetes obstacle that affects eyes. It's caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina). Diabetic retinopathy usually affects both the eyes.

To look at the PDF Sample Report and get 30 minutes of a free consultation @ https://www.reportsanddata.com/sample-enquiry-form/1484

Companies considered and profiled in this market study

Bayer AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals Inc., Novartis AG, Valeant Pharmaceuticals International Inc., Abbott Laboratories Ltd., Alimera Sciences Inc., AmPio Pharmaceuticals Inc., Bausch & Lomb Inc., Boehringer Ingelheim GmbH, iCo Therapeutics Inc., Lupin Ltd., PAREXEL International Corp., Quark Pharmaceuticals Inc., Thrombogenic NV, and Vitreoretinal Technologies Inc

As the condition progresses, diabetic retinopathy symptoms typically include; spots or dark strings floating in your vision (floaters)blurred vision, fluctuating vision, impaired color vision, dark or empty areas in your vision and also vision loss. Diabetic retinopathy damages the blood vessels within the retinal tissue, causing them to leak fluid and distort vision. Excess of sugar intake in blood can lead to the blockage of the tiny blood vessels that nourish the retina, cutting off its blood supply. As a result, the eye attempts to grow new blood vessels nonetheless these new blood vessels don't mature properly and can leak easily. There are two types of diabetic retinopathy viz, early diabetic retinopathy and advanced diabetic retinopathy.

The line of treatment for diabetic retinopathy depends exclusively on extremity of the condition and may require intraocular injections, anti-VEGF drugs, laser surgery or vitrectomy. Growing incidence of diabetes along with rising incidence of blindness because of diabetes is predicted to drive the market growth during the forecast period. Moreover, increase in purchasing power and the dread of losing vision have augmented the expenditure by patients to avail the indispensable treatment. Availability of advanced technology and minimal pain inducing laser procedure topped with quick recovery is likely to promote patients' inclination to adopt surgical treatments. North American section accounted for the largest share of 36.8% due to the supportive compensation strategies, and increasing prevalence of diabetes.

Key findings from the report

1. World Health Organization in 2016, estimated that 1.6 million deaths were directly caused by diabetes. WHO estimates that diabetes was the seventh leading cause of deaths

2. Non-proliferative diabetic retinopathy has registered highest CAGR of 7.5% and is successful in dominating the market with market share of 56%. The most common reason for blindness in people suffering from diabetes is non-proliferative

3. According to the estimates of the screening conducted by the All India Ophthalmological Society, the prevalence of diabetic retinopathy in the data set collected by them was approximately calculated to 21.7%

4. Approximately 1.5% adults suffering from diabetes were affected from proliferative diabetic retinopathy in the U.S. in the recent past

5. Asia-Pacific regional segment of the diabetic retinopathy market is expected to register itself as highest growing segment during the forecasted period, at a CAGR of 8.3%; owing it to the qualitative as well as quantitative market potential offered in developing nations such as China & India

Ask Here to Get customization & Check for irresistible discount rates on this report @ https://www.reportsanddata.com/discount-enquiry-form/1484

Segments covered in this market study

This report about global diabetic retinopathy market forecasts revenue growth at a global, regional and country level also, provides an analysis on the industry trends in each of the sub segments from 2016 to 2026. For the purpose of this study, the market is segmented on the basis of type, management, distribution channel and regions:

Type (Revenue in USD Million; 2016-2026)

Proliferative diabetic retinopathy
Non-proliferative diabetic retinopathy
Mild
Moderate
Severe

Management (Revenue in USD Million; 2016-2026)

Anti-VEGF
Intraocular steroid injection
Laser surgery
Vitrectomy

Distribution channel (Revenue in USD Million; 2016-2026)

Eye clinics
Hospital and pharmacies
Ambulatory surgical centers
Other

Regional Outlook (Revenue in USD Million; 2016-2026)

North America
Europe
Asia Pacific
Middle East & Africa
Latin America

Find the extensive Report Description, TOC and Table of Figure @ https://www.reportsanddata.com/report-detail/diabetic-retinopathy-market

Key selling points of this research study

1. The study gives an in-depth evaluation of the evolving competitive scenario that gives the reader/client a competitive edge.

2. It offers a holistic view of all critical aspects boosting or limiting the growth of the sector

3. The market intelligence report derives an eight-year forecast, including historical, contemporary, and potential market prospects, projecting the estimated progress of the market.

4. It aids informed decision-making by offering an exhaustive database of the pivotal market segments and sub-segments.

Contact Us:

John Watson
Head of Business Development
Reports And Data
40 Wall St. 28th floor New York City, NY 10005 United States
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client's make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.

This release was published on openPR.